Coldstream Laboratories announces manager of technology transfer
Sholto Maclean takes newly created role at Kentucky firm
In this newly created position, Maclean will work with Coldstream's pharmaceutical development team to scale up processes for sterile liquid and lyophilised drug products for manufacturing in the company's sterile facility.
Maclean has more than 20 years of experience in parenteral processing, sterile product development, lyophilisation development and aseptic manufacturing. Most recently, he was a lyophilisation/technology transfer consultant for a major pharmaceutical company. Previous roles include positions at GlaxoSmithKline and DSM Pharmaceuticals.
Coldstream Laboratories operates the only sterile pharmaceutical manufacturing facility in Kentucky.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months